BioSpace News Archive

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004.

Inflammatix, Inc., a pioneering molecular diagnostics company, announced today the appointment of Purvesh Khatri, PhD, as Chief Scientific Officer.

Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the CROPS 2022: Improving Agriculture Through Genomics Conference taking place June 13 through June 16, 2022 in Huntsville, Alabama.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced it has secured a license and distribution agreement with Hong Kong WinHealth Pharma Group Ltd. for its lead product candidate, QRX003 for Netherton Syndrome as well as for a second pipeline product, QRX004 for Epidermolysis Bullosa.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced a prospective study to evaluate the TCAR® system in the treatment of standard surgical risk patients with carotid artery disease.

GC Aesthetics®, Inc., a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced , its growth and expansion plans for the Brazilian market, the second largest Breast Augmentation market in the world.

PulmoSeekTM Lung Cancer Early Detection Assay, the non-invasive blood-based cfDNA methylation detection product developed by AnchorDx for the early diagnosis of lung cancer, recently completed the procedure for EU IVDD CE Marking, and obtained IVD reagents licensing signed and issued by the CIBG of Ministry of Health, Welfare and Sport in the Netherlands.

Halia Therapeutics , a clinical-stage biotechnology company discovering and developing small molecule therapeutics to treat inflammatory diseases, today announced that the first participant in a Phase 1 clinical study has been dosed with HT-6184, a novel small molecule inhibitor of NEK7 and the NLRP3 pathway.

Mitsubishi Tanabe Pharma America, Inc. announced RADICAVA ORS® is now available in the United States for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that currently has no cure and can progress rapidly.

Allarity Therapeutics, Inc. announced the appointment of Roberto Pili, M.D., as a member of the Company’s Scientific Advisory Board.